Prognostic Impact of 18-F-Florbetaben Amyloid PET Imaging in Patients with Isolated Increases in Cerebrospinal Fluid Phospho-Tau Biomarkers: A Longitudinal Study

This longitudinal study evaluates the prognostic impact of amyloid PET in patients suspected of Alzheimer's disease and presenting with isolated cerebrospinal fluid (CSF) increases in P-Tau proteins (NCT02556502). The rate of conversion, based on the DSM-5 criteria and all collected data (average follow-up of 39.2 +/- 13.2 months), was determined by a panel of experts blinded to the PET results and was 75% (6/8) for positive and 35% (6/17) for negative baseline amyloid PET. In this population with isolated CSF increases in P-Tau, a positive baseline amyloid PET was associated with greater than twice the proportion of dementia conversions within the following three years.

Automated summary

This study found that in patients suspected of having Alzheimer's disease with isolated cerebrospinal fluid increases in P-Tau proteins, a positive baseline amyloid PET was associated with more than twice the proportion of dementia conversions within the following three years.